A look at how Boston Scientific has shaped the emerging med tech landscape, and where the ex-BSC-ers are making their impact now.

Johnson & Johnson’s (NYSE:JNJ) Michael Mahoney will begin leading Boston Scientific (NYSE:BSX) in October, first as president and then begin his tenure at CEO in November. Mahoney joins Boston Scientific at a challenging time, as the company struggles with limited growth in its heart device markets, which generate 70 percent of its total [...]

Paulson & Co. Inc. is Boston Scientific Corp.’s (NYSE:BSX) largest shareholder no more, after liquidating its position in BSX completely by selling off some 15 million shares of the Natick, Mass.-based medical device company during the second quarter.The New York-based fund has been steadily selling off its BSX shares for more than [...]

The cardiac rhythm management industry looks like it needs of a jolt of its own, badly.A look at the earnings releases of two of the big three players in the CRM Market, Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ), reveals that the slump in the cardiac rhythm management business is more persistent than some [...]

Shares of Boston Scientific Corp. (NYSE:BSX) traded at unusually high volumes for two straight weeks during the recent roller coast on Wall Street, coming in at more than 120 million trades during the week ending July 29 and topping 140 million the week ending August 5.Last week shaped up to top [...]

Boston Scientific Corp. (NYSE:BSX) plans to spend $37 million on overseas research and development, this time at its R&D facility in Clonmel, Ireland.The Natick, Mass.-based company hopes to jump-start development of a next generation cardiac rhythm management system.The funding is partially supported by a grant from IDA Ireland, a quasi-public investment promotion agency, which also [...]

In the stockapocalypse that was Manic Monday, medical technology and pharma stocks got a mere slap on the wrist compared with banking stocks that received a more humiliating pants-down whipping.It appears that pharma stocks fared better than medical device and biotech stocks. GlaxoSmithKline (NYSE:GSK) was down a mere 28 cents to close at $39.44 on [...]

The shakeup at Boston Scientific (NYSE:BSX) last week proved that while the sheriff may be headed for the sunset, he’s not ready to hang up his spurs just yet.With little more than a month past his two year anniversary of taking the helm at BSX, J. Raymond Elliott continues to re-shape the Natick, [...]

A rebounding Boston Scientific Corp. (NYSE:BSX) said it plans to eliminate up to 1,400 jobs as part of a restructuring program aimed at saving between $225 million to $275 million annually by 2013.The job cuts are “designed to strengthen operational effectiveness and efficiencies, increase competitiveness and support new investments, thereby increasing shareholder value,” according to [...]

Boston Scientific Corp. (NYSE:BSX) sank $150 million into a five-year plan to expand Chinese commercial operations, including establishing a wholly owned manufacturing site and developing training centers for Chinese health care providers.The Natick, Mass.-based med-tech giant also plans to increase its Chinese workforce six-fold from 200 to more than 1,200 while investing further in R&D [...]